CRBP: Corbus Pharmaceuticals Holdings Inc

CRBP新闻

• 14:15 Can Cannabis Stocks Reverse Their Prolonged Downtrend?
• 21:41 Corbus (CRBP) Q2 Loss Beats Estimates
• 15:37 Corbus to present updated CRB-701 cancer drug data at ESMO 2025
• 15:07 Corbus Pharmaceuticals stock rises after ESMO abstract acceptance
• 12:25 Corbus begins multiple ascending dose portion of CRB-913 obesity trial
• 13:04 Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab
• 20:16 Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium
• 19:42 Corbus Pharmaceuticals: Is Its Pipeline Really Worthless After Negative Data?
• 11:50 H.C. Wainwright maintains buy rating and $40 target for Corbus stock
• 12:32 Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
• 11:29 Mizuho cuts Corbus Pharma stock target to $32, keeps Outperform
• 18:17 Corbus Pharmaceuticals Highlights Data From Its First US-Based Trial Of Lead Cancer Drug Candidate - Corbus Pharmaceuticals (NASDAQ:CRBP)